相关实验视频

Updated: Jul 9, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

治疗巴里西提尼布的慢性行为性皮肤炎的缓解:一个病例报告

Jessica Maguire¹, David Gleeson¹, Roberto Corso¹

¹St John's Institute of Dermatology Guy's and St Thomas' NHS Foundation Trust London UK.

Skin health and disease

|December 4, 2023

概括

雅努斯酶抑制剂 (JAKi) 为慢性行为性皮肤炎 (CAD) 提供了一个有前途的新疗法,这是一种严重的皮肤疾病. 这项案例研究表明,巴里西丁尼在耐火性CAD患者的症状和过敏测试结果显著改善.

科学领域:

免疫皮肤学免疫皮肤学
摄影皮肤病学摄影皮肤病学
药理学药理学是指药理学的学科.

背景情况:

慢性行为性皮肤炎 (CAD) 是一种免疫媒介的光皮病,导致湿疹性,性皮肤变化.
目前对CAD病理生理学的理解是有限的,涉及过敏和过敏原交叉反应.
CAD 常常抗拒标准的免疫抑制治疗,严重影响患者的生活质量.

研究的目的:

为了呈现一种严重的病例,耐治疗的CAD成功地用Janus激酶抑制剂 (JAKi) 治疗.
评估巴里西提尼布在改善CAD临床症状和免疫标记物的疗效.
探索JAK抑制剂作为CAD新治疗策略的潜力.

主要方法:

一个69岁的男性患者的病例报告,患有严重的,耐火性CAD.
用JAK抑制剂巴里西提尼布作为单剂疗法的治疗.
评估临床改善,照片测试和治疗前后的贴片测试结果.

主要成果:

患者经历了巴里替尼治疗的显著临床改善.
观察到照片测试结果的正常化和补丁测试结果的改善.
这一案例为JAK抑制剂在CAD中的有效性提供了进一步的证据,包括免疫学标记.

结论:

简氏激酶抑制剂 (JAKi) 代表了一种潜在的新疗法途径,用于使慢性行为性皮肤炎致残.
巴里西替尼在患有严重,耐火性CAD的患者中表现出显著的疗效.
观察到的照片和贴片测试的正常化表明,JAKi可能会调节CAD中潜在的过敏机制.

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...